证券代码：688687 证券简称：凯因科技 北京凯因科技股份有限公司 投资者关系活动记录表 关于 2023 年度业绩说明会召开情况说明 投资者关系活动类 别 □特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 □新闻发布会 □路演活动 □现场参观 □一对一沟通 □其他（电话会议） 时间 2024 年 4 月 10 日 15:00-16:00 地点 公司会议室 会议召开方式 网络文字互动方式 公司接待人员姓名 董事长兼总裁 周德胜先生 副总裁兼董事会秘书 赫崇飞先生 首席财务官 郭伟先生 独立董事 杜臣先生 开场致辞 尊敬的各位投资者，大家下午好！ 非常感谢大家在百忙之中参加北京凯因科技股份有限公司 2023 年度业绩说明会。在此，我谨代表公司向参加本次业绩 说明会的广大投资者表示热烈的欢迎，向关心和支持凯因科技 （2023 年度业绩说明会） - 1 - 北京凯因科技股份有限公司 2 / 8 | | 发展的社会各界朋友致以衷心的感谢！ | | --- | --- | | | 公司希望通过本次说明会能帮助大家更加全面、深入地认 | | | 识和了解公司，增进同社会各界朋友的交流与沟通。希望大家 | | | 能 ...

证券代码：688687 证券简称：凯因科技 北京凯因科技股份有限公司 投资者关系活动记录表 （2023 年度业绩说明会） ...

Investment Rating - The report maintains a "Recommended" rating for the company [3][10]. Core Viewpoints - The company focuses on the antiviral field with stable main business operations, achieving a revenue of 1.412 billion yuan in 2023, a year-on-year increase of 21.73%, and a net profit attributable to shareholders of 117 million yuan, up 39.71% [3]. - The company is deepening its market strategy for key products, with significant growth in chemical drug sales, particularly for hepatitis C products, which have seen a sales revenue increase of 92.66% year-on-year [3]. - The company is steadily increasing its R&D investment, with multiple clinical projects making progress, including the approval of new drug KW027 for clinical trials [3]. Financial Forecasts and Key Indicators - The company is projected to achieve revenues of 1.699 billion yuan in 2024, 2.109 billion yuan in 2025, and 2.676 billion yuan in 2026, with corresponding net profits of 151 million yuan, 194 million yuan, and 257 million yuan respectively [6][11]. - The expected growth rates for revenue are 20.35% in 2024, 24.10% in 2025, and 26.89% in 2026 [6][11]. - The projected PE ratios are 31 for 2024, 24 for 2025, and 18 for 2026, indicating a favorable valuation trend [6][11].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 212,673,809.18, representing a year-on-year increase of 10.34%[2] - The net profit attributable to shareholders for the same period was CNY 22,144,168.59, reflecting a growth of 4.75%[2] - The net profit after deducting non-recurring gains and losses decreased by 4.21% to CNY 20,280,955.12[2] - Total operating revenue for Q1 2024 reached ¥212,673,809.18, an increase of 10.1% compared to ¥192,744,105.30 in Q1 2023[16] - Net profit attributable to shareholders of the parent company for Q1 2024 was ¥22,144,168.59, compared to ¥21,139,765.72 in Q1 2023, representing a growth of 4.8%[18] - The company reported a net profit margin of approximately 11.3% for Q1 2024, compared to 11.5% in Q1 2023, indicating a slight decline in profitability[18] Cash Flow - The net cash flow from operating activities was negative at CNY -21,401,412.37, indicating a significant cash outflow[2] - In Q1 2024, the cash received from sales and services amounted to ¥244,798,722.37, an increase of 28% compared to ¥191,155,730.03 in Q1 2023[20] - The net cash flow from operating activities was -¥21,401,412.37, an improvement from -¥91,540,826.82 in the same period last year[20] - The company reported a total cash outflow from operating activities of ¥276,200,897.27, down from ¥290,111,849.49 in Q1 2023[20] - The company experienced a net decrease in cash and cash equivalents of ¥10,405,543.02 in Q1 2024, contrasting with an increase of ¥48,108,510.74 in Q1 2023[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,423,496,174.26, down 1.01% from the end of the previous year[3] - The company reported a total asset value of ¥2,423,496,174.26 as of the end of Q1 2024, a slight decrease from ¥2,448,207,848.87 at the end of Q1 2023[14] - Total liabilities amounted to ¥613,865,721.80 in Q1 2024, down from ¥663,013,024.25 in Q1 2023, indicating a reduction of approximately 7.4%[14] Research and Development - Research and development expenses totaled CNY 29,061,914.47, accounting for 13.67% of operating revenue, a decrease of 1.19 percentage points[3] - Research and development expenses for Q1 2024 were ¥22,491,555.38, slightly down from ¥23,075,845.01 in Q1 2023, showing a decrease of 2.5%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,680[7] - The largest shareholder, Beijing Song'an Investment Management Co., Ltd., held 22.46% of the shares, totaling 38,400,000 shares[7] - There were no significant changes in the top ten shareholders or their shareholding percentages compared to the previous period[9] Government Subsidies - The company received government subsidies amounting to CNY 1,537,415.64, which are closely related to its normal business operations[4] Current Assets - As of March 31, 2024, the company's total current assets amounted to RMB 1,764,139,425.69, a decrease from RMB 1,821,697,131.03 as of December 31, 2023, representing a decline of approximately 3.14%[12] - The company's cash and cash equivalents decreased to RMB 824,387,398.81 from RMB 853,631,795.13, reflecting a reduction of about 3.43%[12] - Accounts receivable decreased significantly to RMB 337,038,126.98 from RMB 397,127,092.13, indicating a decline of approximately 15.14%[12] - The company's inventory also saw a decrease, dropping to RMB 135,791,373.51 from RMB 139,537,381.08, which is a reduction of about 2.63%[12] - The total non-current assets remained stable at RMB 4,286,415.83 for long-term equity investments, unchanged from the previous period[12] - The company's fixed assets increased to RMB 203,187,016.97 from RMB 190,964,534.22, marking an increase of approximately 6.36%[12] - The company reported a significant increase in prepayments, rising to RMB 25,572,234.81 from RMB 13,288,857.49, which is an increase of approximately 92.67%[12] Taxation - The company paid ¥28,148,082.19 in taxes during Q1 2024, significantly higher than ¥10,802,709.99 in Q1 2023[20] Other Information - The company's total liabilities and equity figures were not disclosed in the provided content, indicating a need for further details in future reports[10] - The company has not disclosed any new product developments or market expansion strategies in the current report[10]

Dividend Distribution - The company plans to distribute a cash dividend of 2.5 yuan per 10 shares, totaling approximately 41,858,848.75 yuan, which represents 35.92% of the net profit attributable to shareholders[6]. - The profit distribution plan has been approved by the board and will be submitted for shareholder approval[8]. - The company reported a cash dividend amount of CNY 41,858,848.75, which is 46.44% of the net profit attributable to ordinary shareholders[199]. - The total dividend amount, including cash buybacks, is CNY 54,117,937.58[199]. - The company has established a clear and complete decision-making process for its dividend policy[197]. - The company ensures that minority shareholders have the opportunity to express their opinions and protect their rights[197]. Financial Performance - The company's operating revenue for 2023 reached ¥1,412,006,182.85, representing a 21.73% increase compared to ¥1,159,973,577.75 in 2022[24]. - The net profit attributable to shareholders for 2023 was ¥116,524,994.34, a 39.71% increase from ¥83,407,819.44 in the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥122,577,218.12, up 124.62% from ¥54,570,001.90 in 2022[24]. - The basic earnings per share for 2023 was ¥0.70, a 42.86% increase compared to ¥0.49 in 2022[25]. - The diluted earnings per share also stood at ¥0.70, reflecting the same growth rate of 42.86% from the previous year[25]. - The total assets of the company increased by 10.79% to ¥2,448,207,848.87 at the end of 2023, compared to ¥2,209,724,972.77 at the end of 2022[24]. - The net assets attributable to shareholders rose by 4.67% to ¥1,753,884,582.61 at the end of 2023, compared to ¥1,675,556,748.68 at the end of 2022[24]. - The cash flow from operating activities for 2023 was ¥126,603,431.56, a decrease of 5.55% from ¥134,048,463.67 in 2022[24]. - The weighted average return on net assets for 2023 was 6.81%, an increase of 1.86 percentage points from 4.95% in 2022[25]. Research and Development - The company continues to focus on the development of innovative drugs and expanding its market presence, particularly in antiviral agents[24]. - The company's R&D expenditure accounted for 12.22% of operating revenue, a decrease of 1.01 percentage points compared to the previous year[26]. - The company applied for 25 invention patents and received 5 authorizations during the reporting period, totaling 53 authorized patents[37]. - R&D investment increased to CNY 172.58 million, up 12.45% year-over-year, accounting for 12.22% of revenue[37]. - The company is focusing on innovative drug development for functional cure combinations for hepatitis B[42]. - The company has formed a multi-target, multi-mechanism R&D pipeline for the treatment of viral hepatitis B, including projects like KW-001 and KW-027[59]. - The company is focusing on innovative drug development for hepatitis B functional cure and immune disease treatment[123]. Market and Sales Performance - The company achieved a total product sales revenue of ¥1,388,489,830.63 in 2023, representing a year-on-year growth of 21.71%[97]. - Chemical drug sales revenue increased by 92.66% year-on-year, primarily driven by the market expansion of hepatitis C products and significant growth in sales of 凯力唯® and 安博司®[95]. - The sales revenue of the product 凯力唯® increased by over 200% year-on-year in 2023, following its inclusion in the national medical insurance directory[72]. - The sales revenue from the four main regions (East China, Southwest, Central China, Northwest) accounted for 72.79% of total sales, with overseas revenue only contributing 0.10%[95]. - The company is focusing on market expansion and product structure adjustment in response to the evolving pharmaceutical procurement policies[95]. Risks and Challenges - The company has outlined various risks in the report, which investors should consider[4]. - The company faces risks related to new drug development, including potential clinical trial failures and regulatory changes[76]. - The company is at risk of losing core technical personnel due to increasing competition in the pharmaceutical industry[78]. - The company’s products face market competition from other direct antiviral drugs, which may impact their market promotion and commercialization[79]. - The company is exposed to risks from fluctuations in raw material supply and prices, which could adversely affect profitability[81]. Corporate Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[10]. - There are no violations of decision-making procedures regarding external guarantees[10]. - The company has not disclosed any special arrangements for corporate governance[9]. - The company has provided a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. - The company conducted 3 meetings of the Audit Committee during the reporting period, reviewing key financial reports and affirming compliance with accounting standards[184]. Employee and Management Information - The company has a total of 584 employees, with 381 in the parent company and 203 in major subsidiaries[187]. - The company has a total of 305 employees with a bachelor's degree or higher, representing approximately 52.2% of the total workforce[187]. - The total pre-tax remuneration for the chairman and president, Zhou Desheng, was 4.21 million CNY for the reporting period[160]. - The total pre-tax remuneration for the vice president and core technology personnel, Shi Jifeng, was 1.75 million CNY for the reporting period[160]. - The total pre-tax remuneration for the chief financial officer, Guo Wei, was 1.19 million CNY for the reporting period[160]. - The total pre-tax remuneration for the chief scientific officer, Wang Tao, was 2.68 million CNY for the reporting period, reflecting an increase due to stock incentive plan vesting[162]. Strategic Initiatives - The company aims to accelerate the sales of new products and increase market share in 2024, focusing on innovative drug development[146]. - The company is enhancing global technical and business cooperation through its Singapore subsidiary to register products in Southeast Asia[149]. - The company plans to implement a new marketing strategy, allocating an additional $10 million for digital marketing initiatives[167]. - The company plans to complete key construction phases of its antibody production base, ensuring efficient operation of the production line[151].

目 录 关于北京凯因科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 1、 专项审计报告 2、 附表 委托单位：北京凯因科技股份有限公司 审计单位：中汇会计师事务所（特殊普通合伙） 联系电话：010-67892271 www.zhcpa.cn 目 景 | 一、关于北京凯因科技股份有限公司 2023 年度非经营性资金占用 | | | --- | --- | | 及其他关联资金往来情况的专项审核说明 | 页 次 1-3 | 二、2023年度非经营性资金占用及其他关联资金往来情况汇总表 l 三、事务所执业资质证明 中国杭州市钱江新域新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5-8 1.2 and 23. Block A. UDC Times Building No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-86879999 Fax. 0571-88879000 关于北京凯因科技股份有限公司 2023 年度非经营性资金占用及其他 关联资金往来情况的专项审核说明 中国杭州市裁江新城新业路8号UDC时 ...

北京凯因科技股份有限公司 独立董事专门会议工作细则 北京凯因科技股份有限公司 独立董事专门会议工作细则 二〇二四年四月 北京凯因科技股份有限公司 独立董事专门会议工作细则 第一章 总则 第一条 为确保北京凯因科技股份有限公司（以下简称"公司"）独立 董事有效履行其职责，进一步提升公司治理水平，根据《中华人民共和国公 司法》《上市公司治理准则》《上市公司独立董事管理办法》《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》《北京凯因科技股 份有限公司章程》（以下简称"《公司章程》"）等有关规定，制定本工作 细则。 第二条 本细则适用于公司独立董事专门会议的召集、召开、决策过程、 记录保存等活动。 第三条 独立董事专门会议是指由公司独立董事组成的会议，旨在独立 履行职责，维护公司整体利益和股东合法权益。 第四条 公司应当为独立董事专门会议的召开提供必要的工作条件和 支持。 第二章 职责与权限 第五条 下列事项应当经公司独立董事专门会议审议，并经全体独立董 事过半数同意后，方可提交董事会审议： （一）应当披露的关联交易； （二）公司及相关方变更或豁免承诺的方案； （三）公司被收购时，董事会针对收购所 ...

证券代码：688687 证券简称：凯因科技 公告编号：2024-019 北京凯因科技股份有限公司 关于 2024 年度申请银行综合授信额度的公告 为提高工作效率，统一授权公司管理层办理上述授信额度申请事宜，并签署 合同、协议、凭证等相关文件。上述授信总额度内的单笔融资不再上报董事会进 行审议表决，由董事长确定并执行。 特此公告。 北京凯因科技股份有限公司董事会 2024 年 4 月 10 日 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京凯因科技股份有限公司（以下简称"公司"）于2024年4月9日召开第五 届董事第二十一次会议，审议通过了《关于公司2024年度申请银行综合授信额度 的议案》。根据《上海证券交易所科创板股票上市规则》及《北京凯因科技股份 有限公司章程》的相关规定，公司本次向银行申请综合授信额度事项不涉及担保 或关联交易，该议案无需提交公司股东大会审议，现将相关事项公告如下： 公司目前经营情况良好，财务状况稳健，为满足经营发展的资金需求，在确 保运作规范和风险可控的前提下，公司计划向兴业银行、建设银行 ...

证券代码：688687 证券简称：凯因科技 公告编号：2024-016 北京凯因科技股份有限公司 关于公司使用部分暂时闲置募集资金 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京凯因科技股份有限公司（以下简称"公司"）于 2024 年 4 月 9 日召开第 五届董事会第二十一次会议、第五届监事会第十五次会议，审议通过了《关于公 司使用部分暂时闲置募集资金进行现金管理的议案》，同意公司在保证不影响募 集资金投资计划正常进行的前提下，使用最高不超过人民币 2.1 亿元的暂时闲置 募集资金进行现金管理，用于投资安全性高，满足保本要求，流动性好的产品（包 括但不限于购买保本型理财产品、结构性存款、大额存单、定期存款、通知存款、 协定存款等），自公司董事会审议通过之日起至下一年年度董事会审议批准闲置 募集资金进行现金管理事项之日止。在前述额度及期限范围内，公司可以循环滚 动使用。公司保荐机构海通证券股份有限公司（以下简称"保荐机构"）发表了 明确同意的意见。公司董事会授权董事长在授权额度和期限内行使进行现金 ...

使用部分暂时闲置募集资金进行现金管理的核查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为北京 凯因科技股份有限公司（以下简称"凯因科技"或"公司"）首次公开发行股票 并在科创板上市持续督导期间的保荐机构，根据《证券发行上市保荐业务管理办 法》《上海证券交易所科创板股票上市规则》等有关法律法规和规范性文件的要 求，对凯因科技首次公开发行限售股上市流通的事项进行了核查，具体情况如下： 海通证券股份有限公司 关于北京凯因科技股份有限公司 三、使用暂时闲置募集资金进行现金管理的基本情况 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意北京凯因科技股份有限公司 首次公开发行股票注册的批复》（证监许可〔2021〕8 号），公司获准向社会公 开发行人民币普通股（A 股）4,246 万股，每股发行价格 18.98 元，募集资金总额 为 80,589.08 万元，扣除发行费用 8,002.47 万元（不含增值税）后，募集资金净 额为 72,586.61 万元。 上述募集资金已全部到位，由中汇会计师事务所（特殊普通合伙）对公司本 次公开发行募集资金到位情况进行了审验，并于 2021 年 2 ...